



\$1642

PATENT
Docket No.: 19603/2595 (CRF D-2400)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Hempstead et al.

Serial No. : 09/830,520, based on PCT/US99/25365

Cnfrm. No. : 9715

Filed : October 28, 1999

For : METHODS FOR REGULATING
ANGIOGENESIS AND VASCULAR
INTEGRITY USING TRK RECEPTOR
LIGANDS

Examiner:
G. Nickol

Art Unit:
1642

RECEIVED
APR 17 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97-1.98

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202
Box:

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form. The pertinence of some of these references is indicated in the International Search Report (copy enclosed) for the corresponding PCT application.

Pursuant to 37 CFR § 1.17(p) and 37 CFR § 1.97(c), applicants hereby enclose a check in the amount of \$180.00. The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 14-1138.

04/16/2003 MH0HAMM1 00000028 09830520

01 FC:1806

180.00 OP

Respectfully submitted,

Date: April 11, 2003

Georgia Evans
Georgia Evans
Registration No. 44,597

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1672
Facsimile: (585) 263-1600

R677148.1

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
U.S. Patent and Trademark Office P.O. BOX 2327
Arlington, VA 22202, on the date below.

Date

Ruth R. Smith

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19603/2595	SERIAL NO. 09/830,520
	APPLICANT Hempstead et al.	
	FILING DATE October 28, 1999	GROUP ART UNIT 1642



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	RECEIVED APR 17 2003 TECH CENTER 1600/2900
	1	4,119,618	10/10/1978	Said			
	2	5,180,820	01/19/1993	Barde et al.			
	3	5,229,500	07/20/1993	Barde et al.			
	4	5,235,043	08/10/1993	Collins et al.			
	5	5,338,840	08/16/1994	Bayne et al.			
	6	5,401,832	03/28/1995	Linemeyer et al.			
	7	5,438,121	08/01/1995	Barde et al.			
	8	5,453,361	09/26/1995	Yancopoulos et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE
	9	WO 95/21193	08/10/1995	WIPO			
	10	WO 96/33731	10/31/1996	WIPO			
	11	WO 97/21732	06/19/1997	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	12	Oikawa et al., "Inhibition of Angiogenesis by Staurosporine, A Potent Protein Kinase Inhibitor," <u>The Journal of Antibiotics</u> , 45(7):1155-1160 (1992)
	13	Hardie, eds. <u>The Protein Kinase Factsbook II: Protein-Tyrosine Kinases</u> , London:Academic Press, pp. 208-217 (1995)
	14	Hempstead, "Strategies for Modulating Trk Receptor Activity," <u>Experimental Neurology</u> , 124:31-36 (1993)
	15	Hempstead et al., "Brain Derived Neurotropic Factor Induces Angiogenesis: Role in Intramyocardial Vessel Development," <u>Blood</u> , 92(10) Suppl. 1 Part 1-2:175A, 40 th Annual Meeting of Am. Soc. Hematol. (1998) (abstract only)
	16	McGregor et al., "Roles of Trk Family Neurotrophin Receptors in Medullary Thyroid Carcinoma Development and Progression," <u>Proc. Natl. Acad. Sci. USA</u> , 96:4540-4545 (1999)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19603/2595	09/830,520
	APPLICANT	
	Hempstead et al.	
	FILING DATE	GROUP ART UNIT
	October 28, 1999	1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	17	5,488,099	01/30/1996	Persson et al.			
	18	5,512,661	04/30/1996	Shooter et al.			
	19	5,534,615	07/09/1996	Baker et al.			
	20	5,654,427	08/05/1997	Dionne et al.			
	21	5,665,862	09/09/1997	Fischbach et al.			
	22	5,672,683	09/30/1997	Friden et al.			
	23	5,712,395	01/27/1998	App et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
	24	WO 98/32859	07/30/1998	WIPO			
	25	WO 00/10552	03/02/2000	WIPO			
	26	WO 99/06073	02/11/1999	WIPO			Abstract

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	27	Donovan et al., "Neurotrophin and Neurotrophin Receptors in Vascular Smooth Muscle Cells," <u>American Journal of Pathology</u> , 147(2):309-324 (1995)
	28	Witzke et al., "Myocardial Ultrastructural Changes Induced by Administration of Nerve Growth Factor," in Gardner, ed., <u>Surgical Forum</u> , Vol. XXVII, Chicago, Illinois: American College of Surgeons, pp. 295-297 (1976)
	29	Kaye et al., "Nerve Growth Factor-Enhanced Reinnervation of Surgically Denervated Canine Heart," <u>Am. J. Physiol.</u> , 236(4):H624-H628 (1979)
	30	Long et al., "Trophic Factors for Cardiac Myocytes," <u>Journal of Hypertension</u> , 8 (suppl 7):S219-S224 (1990)
	31	Santos et al., "Nerve Growth Factor: Increased Angiogenesis Without Improved Nerve Regeneration," <u>Otolaryngol. Head Neck Surg.</u> , 105:12-25 (1991)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19603/2595	SERIAL NO. 09/830,520
	APPLICANT Hempstead et al.	
	FILING DATE October 28, 1999	GROUP ART UNIT 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	32	5,733,727	03/31/1998	Field			
	33	5,733,871	03/31/1998	Alps et al.			
	34	5,739,113	04/14/1998	Lee			
	35	5,747,655	05/05/1998	Johnson, Jr. et al.			
	36	5,750,373	05/12/1998	Garrard et al.			
	37	5,763,441	06/09/1998	App et al.			
	38	5,763,584	06/09/1998	Godowski			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
	39	WO 99/21590	05/06/1999	WIPO			Abstract
	40	WO 98/13071	04/02/1998	WIPO			Abstract
	41	WO 98/49300	11/05/1998	WIPO			Abstract

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	42	Scarlsbrick et al., "Coexpression of mRNAs for NGF, BDNF, and NT-3 in the Cardiovascular System of the Pre- and Postnatal Rat," <u>J. Neurosci.</u> , 13(3):875-893 (1993)
	43	Tsukahara et al., "The Role of Brain-Derived Neurotrophic Factor in Transient Forebrain Ischemia in the Rat Brain," <u>Neurosurgery</u> , 34:323-331 (1994)
	44	Hassankhani et al., "Overexpression of NGF Within the Heart of Transgenic Mice Causes Hyperinnervation, Cardiac Enlargement, and Hyperplasia of Ectopic Cells," <u>Development Biology</u> , 169:309-321 (1995)
	45	Andrade-Rozental et al., "Characterization of Two Populations of Ectopic Cells Isolated from the Hearts of NGF Transgenic Mice," <u>Developmental Biology</u> , 169:533-546 (1995)
	46	Milner et al., "Nerve Growth Factor Treatment of Adult Rats Selectively Enhances Innervation of Urinogenital Tract Rather Than Vascular Smooth Muscle, <u>Int. J. Devl. Neuroscience</u> , 13(5):393-401 (1995)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19603/2595	SERIAL NO. 09/830,520
	APPLICANT Hempstead et al.	
	FILING DATE October 28, 1999	GROUP ART UNIT 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPRO- PRIATE
	47	5,770,577	06/23/1998	Kinstler et al.			
	48	5,817,471	10/06/1998	Kaplan et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
	49	WO 99/40945	08/19/1999	WIPO			Abstract
	50	WO 99/50403	10/07/1999	WIPO			Abstract
	51	WO 99/26480	06/03/1999	WIPO			Abstract

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	52	Lam et al., "Increased Nerve Growth Factor Inducible-A Gene and C-FOS Messenger RNA Levels in the Rat Midbrain and Hindbrain Associated with the Cardiovascular Response to Electrical Stimulation of the Mesencephalic Cuneiform Nucleus," <u>Neuroscience</u> , 71(1):193-211 (1996)
	53	Donovan et al., "Identification of an Essential Nonneuronal Function of Neurotrophin 3 in Mammalian Cardiac Development," <u>Nature Genetics</u> , 14:210-213 (1996)
	54	Chan et al., "Neurotrophin-4/5 Treatment Reduces Infarct Size in Rats with Middle Cerebral Artery Occlusion," <u>Neurochemical Research</u> , 21(7):763-767 (1996)
	55	Abe et al., "Protective Role of Nerve Growth Factor Against Postischemic Dysfunction of Sympathetic Coronary Innervation," <u>Circulation</u> , 95:213-220 (1997)
	56	Hempstead et al., "Brain Derived Neurotrophic Factor is Required for the Formation of the Atrial Septum and Coronary Angiogenesis," <u>Molecular Biology of the Cardiovascular System</u> , Keystone Symposia, Abstract 119 (1998) (abstract only)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19603/2595	09/830,520
	APPLICANT	
	Hempstead et al.	
	FILING DATE	GROUP ART UNIT
	October 28, 1999	1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	57	Donovan, "Brain Derived Neurotrophic Factor is an Endothelial Cell Survival Factor Required for Intramyocardial Vessel Stabilization," <u>Development</u> , 127:4531-4540 (2000)
	58	Jones et al., "Targeted Disruption of the BDNF Gene Perturbs Brain and Sensory Neuron Development but Not Motor Neuron Development," <u>Cell</u> , 76:989-999 (1994)
	59	Ernfors et al., "Mice Lacking Brain-Derived Neurotrophic Factor Develop With Sensory Deficits," <u>Nature</u> , 368:147-150 (1994)
	60	Hiltunen et al., "Expression of mRNAs for Neurotrophins and Their Receptors in Developing Rat Heart," <u>Circ. Res.</u> , 79:930-939 (1996)
	61	Leibrock et al., "Molecular Cloning and Expression of Brain-Derived Neurotrophic Factor," <u>Nature</u> , 341:149-152 (1989)
	62	Rayburn et al., "Histologic Examination of the Placenta in the Growth-Retarded Fetus," <u>Am. J. Perinatol.</u> , 6(1):58-61 (1989) (abstract only)
	63	Erickson et al., "Mice Lacking Brain-Derived Neurotrophic Factor Exhibit Visceral Sensory Neuron Losses Distinct from Mice Lacking NT4 and Display a Severe Developmental Deficit in Control of Breathing," <u>J. Neurosci.</u> , 16(17):5361-5371 (1996)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19603/2595	09/830,520
	APPLICANT	
	Hempstead et al.	
	FILING DATE	GROUP ART UNIT
	October 28, 1999	1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

64	Kobayashi et al., "BDNF and NT-4/5 Prevent Atrophy of Rat Rubrospinal Neurons after Cervical Axotomy, Stimulate GAP-43 And α 1-Tubulin mRNA Expression, and Promote Axonal Regeneration," <u>J. Neurosci.</u> , 17(24):9583-9595 (1997)
65	Ibáñez, "Neurotrophin-4: The Odd One Out in the Neurotrophin Family," <u>Neurochemical Research</u> , 21(7):787-793 (1996)
66	Wang et al., "Localized Synaptic Actions of Neurotrophin-4," <u>J. Neurosci.</u> , 18(13):4985-4992 (1998)
67	Ilag et al., "Pan-Neurotrophin 1: A Genetically Engineered Neurotrophic Factor Displaying Multiple Specificities in Peripheral Neurons In vitro and In vivo," <u>Proc. Natl. Acad. Sci. USA</u> , 92(2):607-611 (1995) (abstract only)
68	Urfer et al., "Specificity Determinants in Neurotrophin-3 and Design of Nerve Growth Factor-Based trkC Agonists by Changing Central Beta-Strand Bundle Residues to Their Neurotrophin-3 Analogs," <u>Biochemistry</u> , 36(16):4775-4781 (1997) (abstract only)
69	Boeshore et al., "TrkB Isoforms with Distinct Neurotrophin Specificities are Expressed in Predominantly Nonoverlapping Populations of Avian Dorsal Root Ganglion Neurons," <u>J. Neurosci.</u> , 19(12):4739-4747 (1999)
70	Chalazonitis, "Neurotrophin-3 as an Essential Signal for the Developing Nervous System," <u>Molecular Neurobiology</u> , 12:39-53 (1996)
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19603/2595	SERIAL NO. 09/830,520
	APPLICANT Hempstead et al.	
	FILING DATE October 28, 1999	GROUP ART U 1642



RECEIVED
 APR 17 2003
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

61	Cardiovascular Disorders, pp. 141, 437-438, 974, 1654-1655, 1658-1659; 1784-1785 (date unknown)
72	Binder et al., "Selective Inhibition of Kindling Development by Intraventricular Administration of TrkB Receptor Body," <i>J. Neurosci.</i> , 19(4):1424-1438 (1999) (abstract only)
73	Zagzag et al., "In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis," <i>Exp. Neurol.</i> , 159(2):391-400 (1999) (abstract only)
74	Holash et al., "New Model of Tumor Angiogenesis: Dynamic Balance Between Vessel Regression and Growth Mediated by Angiopoietins and VEGF," <i>Oncogene</i> , 18(38):5356-5362 (1999) (abstract only)
75	Hayes et al., "Angiopoietin-1 and Its Receptor Tie-2 Participate in the Regulation of Capillary-Like Tubule Formation and Survival of Endothelial Cells," <i>Microvasc. Res.</i> , 58(3):224-237 (1999) (abstract only)
76	Segal et al., "Differential Utilization of Trk Autophosphorylation Sites," <i>J. Biol. Chem.</i> , 271(33):20175-20181 (1996) (abstract only)
77	Fandl et al., "Characterization and Crystallization of Recombinant Human Neurotrophin-4," <i>J. Biol. Chem.</i> , 269(1):755-759 (1994) (abstract only)
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19603/2595	09/830,520
	APPLICANT	
	Hempstead et al.	
	FILING DATE	GROUP ART UNIT
	October 28, 1999	1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

78	Ibanez et al., "Neurotrophin-4 is a Target-Derived Neurotrophic Factor for Neurons of the Trigeminal Ganglion," <u>Development</u> , 117(4):1345-1353 (1993) (abstract only)
79	Ip et al., "Mammalian Neurotrophin-4: Structure, Chromosomal Localization, Tissue Distribution, and Receptor Specificity," <u>Proc. Natl. Acad. Sci. USA</u> , 89(7):3060-3064 (1992) (abstract only)
80	Hallbook et al., "Evolutionary Studies of the Nerve Growth Factor Family Reveal a Novel Member Abundantly Expressed in Xenopus Ovary," <u>Neuron</u> , 6(5):845-858 (1991) (abstract only)
81	Holash et al., "Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF, <u>Science</u> , 284:1994-1998 (1999)
82	Papapetropoulos et al., "Direct Actions of Angiopoietin-1 on Human Endothelium: Evidence for Network Stabilization, Cell Survival, and Interaction with Other Angiogenic Growth Factors," <u>Laboratory Investigation</u> , 79(2):213-223 (1999)
83	Hempstead et al., "Brain Derived Neurotrophic Factor is Required for the Formulation of the Atrial Septum and Coronary Angiogenesis," Weinstein Cardiovascular Development Conference, Vanderbilt University, Nashville, TN, E20 (May 28-30, 1998) (abstract only)
84	Siemeister et al., "Two Independent Mechanisms Essential for Tumor Angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering with Either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway," <u>Cancer Res.</u> , 59(13):3185-3191 (1999) (abstract only)
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19603/2595	09/830,520
	APPLICANT	
	Hempstead et al.	
FILING DATE	GROUP ART UNIT	
October 28, 1999	1642	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	85	Otani et al., "Expressions of Angiopoietins and Tie2 in Human Choroidal Neovascular Membranes," <u>Invest. Ophthalmol. Vis. Sci.</u> , 40(9):1912-1920 (1999) (abstract only)
	86	Goede et al., "Analysis of Blood Vessel Maturation Processes During Cyclic Ovarian Angiogenesis," <u>Lab. Invest.</u> , 78(11):1385-1394 (1998) (abstract only)
	87	Mack et al., "Biologic Bypass with the Use of Adenovirus-Mediated Gene Transfer of the Complementary Deoxyribonucleic Acid for Vascular Endothelial Growth Factor 121 Improves Myocardial Perfusion and Function in the Ischemic Porcine Heart," <u>J. Thorac. Cardiovasc. Surg.</u> , 115(1):168-176 (1998) (abstract only)
	88	Magovern et al., "Direct In vivo Gene Transfer to Canine Myocardium Using a Replication-Deficient Adenovirus Vector," <u>Ann. Thorac. Surg.</u> , 62(2):425-433 (1996) (abstract only)
	89	Symes et al., "Gene Therapy with Vascular Endothelial Growth Factor for Inoperable Coronary Artery Disease," <u>Ann. Thorac. Surg.</u> , 68(3):830-836 (1999) (abstract only)
	90	Losordo et al., "Gene Therapy for Myocardial Angiogenesis," <u>Am. Heart J.</u> , 138(2 Pt. 2):132-141 (1999) (abstract only)
	91	Losordo et al., "Gene Therapy for Myocardial Angiogenesis: Initial Clinical Results with Direct Myocardial Injection of phVEGF165 as Sole Therapy for Myocardial Ischemia," <u>Circulation</u> , 98(25):2800-2804 (1996) (abstract only)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		